Canakinumab is in clinical development for the treatment of adults with Schnitzler syndrome. Schnitzler syndrome is a rare inflammatory condition. The exact underlying cause is currently unknown, however certain proteins of the immune system (including cytokines) play a role in the development of the inflammation in Schnitzler syndrome. The first clinical sign of this condition is usually a mildly or non-itchy skin rash; other symptoms include fevers, joint pain and inflammation, enlarged internal organs, bone pain and muscle aches. There are currently no approved treatments for Schnitzler syndrome.
Canakinumab for Schnitzler syndrome
Canakinumab is in clinical development for the treatment of adults with Schnitzler syndrome. Schnitzler syndrome is a rare inflammatory condition. The exact underlying cause is currently unknown, however certain proteins of the immune system (including cytokines) play a role in the development of the inflammation in Schnitzler syndrome.
Interventions:
Canakinumab (Ilaris; ACZ885)
Indications:
Schnitzler syndrome
Therapeutic Areas:
Immunology
Year:
2021